BWAY Stoklara Genel Bakış BrainsWay Ltd. Amerika Birleşik Devletleri, Doğu Asya ve uluslararası alanda ruh sağlığı bozuklukları için noninvaziv nörostimülasyon tedavileri geliştirmekte ve satmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Not ekleyinFiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti BrainsWay Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı ₪17.14 52 Haftanın En Yüksek Seviyesi ₪20.56 52 Haftanın En Düşük Seviyesi ₪9.35 Beta 0.40 1 Aylık Değişim -5.36% 3 Aylık Değişim 12.10% 1 Yıllık Değişim 37.45% 3 Yıllık Değişim 40.72% 5 Yıllık Değişim 0.47% Halka arzdan bu yana değişim 11.13%
Son Haberler & Güncellemeler
BrainsWay Ltd. Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder Dec 13
BrainsWay Ltd. Reports Promising Feasibility Data Showing Pain Reduction with Deep Tms Therapy Nov 21
New minor risk - Shareholder dilution Nov 16
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.01 loss in 3Q 2023) Nov 14
BrainsWay Ltd. Raises Earnings Guidance for the Full Year 2024 Nov 13
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31 Daha fazla güncelleme görün
BrainsWay Ltd. Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder Dec 13
BrainsWay Ltd. Reports Promising Feasibility Data Showing Pain Reduction with Deep Tms Therapy Nov 21
New minor risk - Shareholder dilution Nov 16
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.01 loss in 3Q 2023) Nov 14
BrainsWay Ltd. Raises Earnings Guidance for the Full Year 2024 Nov 13
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
BrainsWay Ltd. to Report Q3, 2024 Results on Nov 22, 2024 Oct 29 BrainsWay Ltd. announced that it has received $20.006615 million in funding from Valor Management LLC Oct 16
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Sep 10
BrainsWay Ltd. Appoints Richard A. Bermudes, M.D. as Chief Medical Officer, Effective September 1, 2024 Aug 29
After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar Aug 23
New major risk - Share price stability Aug 07
Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.05 loss in 2Q 2023) Aug 07 BrainsWay Ltd. Updates Revenue Guidance for the Full Year of 2024 Aug 07
BrainsWay Ltd. to Report Q2, 2024 Results on Aug 06, 2024 Jul 23
BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024 Jun 13
BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression Jun 05
BrainsWay Ltd., Annual General Meeting, Jun 17, 2024 May 14
First quarter 2024 earnings released: EPS: US$0.003 (vs US$0.07 loss in 1Q 2023) May 09
BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024 May 09
We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth May 03
BrainsWay Ltd. to Report Q1, 2024 Results on May 08, 2024 Apr 26
BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a Novel Therapeutic Approach for Parkinson's Disease Apr 05
Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis Mar 29
Full year 2023 earnings released: US$0.13 loss per share (vs US$0.41 loss in FY 2022) Mar 07
New major risk - Revenue and earnings growth Mar 07
Brainsway Ltd. Provides Earnings Guidance for Full Year 2024 Mar 06
BrainsWay Ltd. to Report Q4, 2023 Results on Mar 06, 2024 Feb 22
New minor risk - Market cap size Jan 24
BrainsWay Ltd. Announces New Rotational Field Technology in Two New Feasibility Studies Jan 10
BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce Dec 25
We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely Dec 21
Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.15 loss in 3Q 2022) Nov 16
BrainsWay Ltd. Announces Publishes the First Coverage Recommendations for Smoking Addiction Treatment Using TMS Nov 04
BrainsWay Ltd. to Report Q3, 2023 Results on Nov 15, 2023 Nov 02
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression Oct 17
We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely Sep 19
Forecast to breakeven in 2025 Aug 10
BrainsWay Ltd. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate Jun 01
Brainsway Ltd. Announces CFO Changes May 24
No longer forecast to breakeven May 18
BrainsWay Ltd. to Report Q1, 2023 Results on May 17, 2023 May 04 Mar 16
Full year 2022 earnings released: US$0.40 loss per share (vs US$0.21 loss in FY 2021) Mar 16 BrainsWay Ltd., Annual General Meeting, Mar 20, 2023
BrainsWay Ltd. Appoints Ami Boehm as an Independent Director Jan 13
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™ Jan 12
Neuronetics Settles Litigation Against BrainsWay Ltd. and BrainsWay USA Inc Jan 11
Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.05 loss in 3Q 2021) Nov 18
No longer forecast to breakeven Nov 16
BrainsWay Ltd. to Report Q3, 2022 Results on Nov 16, 2022 Nov 03
BrainsWay Ltd Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS Sep 15
BrainsWay Ltd. Receives New FDA Clearance for Treating Depression and Anxious Depression Aug 30
We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth Aug 15
Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.06 loss in 2Q 2021) Aug 12
No longer forecast to breakeven Aug 10
BrainsWay Ltd. to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
BrainsWay Ltd. Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression Jun 29
Brainsway Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™ Jun 22
BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer May 13
BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans May 13
First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.11 loss in 1Q 2021) May 12
Neuronetics, Inc. Files Federal Lawsuit Against BrainsWay Ltd. for Misleading Psychiatrists and Patients May 12
BrainsWay Ltd. to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society May 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 10
BrainsWay Ltd. to Report Q4, 2021 Results on Mar 09, 2022 Mar 01
BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business Jan 31
BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System Jan 13
Forecast to breakeven in 2024 Jan 01
Brainsway Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects Dec 10
Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.04 loss in 3Q 2020) Nov 18
Forecast to breakeven in 2023 Nov 18
FDA Clears BrainsWay Deep TMS System for Decreasing Anxiety Symptoms in Depressed Patients Aug 19
Second quarter 2021 earnings released: EPS US$0.06 (vs US$0.03 loss in 2Q 2020) Aug 12
BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield Licensee HCSC Jun 03
BrainsWay Announces First Draft Proposal for Obsessive-Compulsive Disorder Coverage Jun 02
BrainsWay Ltd. Announces First of Its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™ May 25
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in 1Q 2020) May 22
Brainsway Ltd. Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder Apr 27
Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019) Apr 21
Full year 2020 earnings released: US$0.24 loss per share (vs US$0.50 loss in FY 2019) Mar 26
Brainsway Ltd. to Report Q4, 2020 Results on Mar 24, 2021 Mar 12
What Is The Ownership Structure Like For Brainsway Ltd. (TLV:BWAY)? Mar 02
Brainsway Ltd. has completed a Follow-on Equity Offering in the amount of $39.287 million. Feb 25
Third quarter 2020 earnings released: US$0.04 loss per share (vs US$0.12 loss in 3Q 2019) Feb 24
Revenue beats expectations Feb 24
New 90-day high: ₪15.53 Feb 18 Brainsway Ltd., Annual General Meeting, Mar 04, 2021
What Type Of Returns Would Brainsway's(TLV:BWAY) Shareholders Have Earned If They Purchased Their SharesFive Years Ago? Jan 25
New 90-day high: ₪14.00 Jan 21
New 90-day high: ₪11.40 Dec 31
Brainsway Ltd. (TLV:BWAY): Is Breakeven Near? Dec 26
Third quarter 2020 earnings released: US$0.04 loss per share Nov 20 Hissedar Getirileri BWAY IL Medical Equipment IL Pazar 7D 0.9% 1.1% 1.3% 1Y 37.4% 19.0% 24.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: BWAY geçen yıl % 19 oranında getiri sağlayan IL Medical Equipment sektörünü aştı.
Getiri vs Piyasa: BWAY geçen yıl % 24.8 oranında getiri sağlayan IL Piyasasını aştı.
Fiyat Oynaklığı Is BWAY's price volatile compared to industry and market? BWAY volatility BWAY Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 7.2% Market Average Movement 4.3% 10% most volatile stocks in IL Market 8.4% 10% least volatile stocks in IL Market 3.0%
İstikrarlı Hisse Senedi Fiyatı: BWAY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: BWAY 'nin haftalık oynaklığı ( 6% ) geçen yıl boyunca sabit kaldı, ancak hala IL hisselerinin %75'inden yüksek.
Şirket Hakkında BrainsWay Ltd. Amerika Birleşik Devletleri, Doğu Asya ve uluslararası alanda ruh sağlığı bozuklukları için noninvaziv nörostimülasyon tedavileri geliştirmekte ve satmaktadır. Majör depresif bozukluklar, endişeli depresyon, obsesif-kompulsif bozukluklar, sigara bağımlılığı, bipolar bozukluklar, travma sonrası stres bozuklukları, şizofreni, Alzheimer hastalığı, otizm, kronik ağrı, multipl skleroz, inme sonrası rehabilitasyon ve Parkinson hastalıklarının tedavisi için Derin Transkraniyal Manyetik Stimülasyon platformu teknolojisi sunmaktadır. Şirket, psikiyatri alanında doktorlara, hastanelere ve tıp merkezlerine hizmet vermektedir.
Daha fazla göster BrainsWay Ltd. Temel Bilgiler Özeti BrainsWay'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? BWAY temel i̇stati̇sti̇kler Piyasa değeri ₪644.33m Kazançlar(TTM ) ₪5.46m Gelir(TTM ) ₪140.61m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) BWAY gelir tablosu (TTM ) Gelir US$38.63m Gelir Maliyeti US$9.82m Brüt Kâr US$28.81m Diğer Giderler US$27.31m Kazançlar US$1.50m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/22 08:18 Gün Sonu Hisse Fiyatı 2024/12/22 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları BrainsWay Ltd. 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Kyle Mikson Cantor Fitzgerald & Co. Raghuram Selvaraju H.C. Wainwright & Co. Jeffrey Cohen Ladenburg Thalmann & Company
Göster 4 daha fazla analist